Press Release: Dupixent® (dupilumab) Phase 3 Results show - GlobeNewswire

Retrieved on: 2023-10-22 19:23:08

Tags for this article:

Sanofi

Monoclonal antibodies

Breakthrough therapy

Food and Drug Administration

Dupilumab

Eosinophilic esophagitis

Regeneron Pharmaceuticals

Prurigo nodularis

Priority review

Casirivimab/imdevimab

Esophagitis

Atopic dermatitis

Click the tags to see associated articles and topics

Press Release: Dupixent® (dupilumab) Phase 3 Results show - GlobeNewswire. View article details on HISWAI: https://www.globenewswire.com/news-release/2023/10/22/2764338/0/en/Press-Release-Dupixent-dupilumab-Phase-3-Results-show-sustained-efficacy-for-up-to-one-year-in-children-1-to-11-years-of-age-with-eosinophilic-esophagitis-EoE.html

Excerpt

Dupixent is a fully human monoclonal antibody that inhibits the ... antibodies and bispecific antibodies, and through ambitious research ...

Article found on: www.globenewswire.com

View Original Article